Agomelatine in the treatment of ADHD
Phase 2
- Conditions
- Disturbance of activity and attention.Disturbance of activity and attention
- Registration Number
- IRCT201312181556N55
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
diagnosis of ADHD based on DSM-IV and age between 6-17 years old.
Exclusion criteria: receiving of any psychotropics drugs during past two weeks; presence of any psychiatric disorders or mental retardation (I.Q. <70) except for ODD; history of allergy to Agomelatine or Ritaline; presence of any medical problem including cardiovascular diseases; presence of uncontrolled seizures; systolic blood pressure more than 120 mm Hg; resting pulse rate less than 60/minute or more than 115/minute; liver enzymes more than normal range.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of ADHD. Timepoint: Week 0 (before treatment) and Weeks 2, 4 and 6 after treatment. Method of measurement: Teacher and Parent ADHD Rating Scale.
- Secondary Outcome Measures
Name Time Method